ELYM NASDAQ

Eliem Therapeutics, Inc. is a clinical-stage biotechnology firm focused on developing therapeutic solutions for conditions characterized by abnormal neuronal excitability. The company aims to fulfill significant unmet medical needs in areas such as chronic pain management, neuropsychiatric illnesses, epilepsy, and other disorders affecting the central and peripheral nervous systems. Their developmental pipeline is highlighted by two primary drug candidates. ETX-810 is currently in Phase IIa clinical studies for the treatment of chronic pain. The second key candidate, ETX-155, is undergoing Phase I clinical trials, with potential applications for major depressive disorder, perimenopausal depression, and focal onset seizures. Beyond these lead assets, Eliem is also cultivating several preclinical programs, including a Kv7 Program targeting pain, epilepsy, and depression, and an Anxiolytic program specifically designed for generalized anxiety disorder. Eliem Therapeutics, Inc. was established in 2018 and is headquartered in Redmond, Washington.